SPRB — Spruce Biosciences Share Price
0.000.00%
Last trade - 00:00- $3.12m
- -$33.89m
- $4.91m
- 20
- 72
- 12
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.11 | ||
| Price to Tang. Book | 0.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -187.4% | ||
| Return on Equity | -100.7% | ||
| Operating Margin | -1143.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 10.09 | 4.91 | 1.6 | 0.17 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Directors
- Michael Grey CHM (68)
- Samir Gharib PRE (30)
- Javier Szwarcberg CEO (52)
- Rosh Dias OTH
- Kirk Ways DRC
- Tiba Aynechi IND (45)
- Dina Chaya IND (51)
- Bali Muralidhar IND (41)
- Niall O'donnell IND (48)
- Camilla Simpson IND (49)
- Daniel Spiegelman IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 13th, 2014
- Public Since
- October 9th, 2020
- No. of Shareholders
- 33
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 42,231,285
- Address
- 611 Gateway Boulevard, Suite 740, SOUTH SAN FRANCISCO, 94080
- Web
- https://sprucebio.com/
- Phone
- +1 4156554168
- Auditors
- BDO USA, LLP
Upcoming Events for SPRB
Spruce Biosciences Inc Annual Shareholders Meeting
Q2 2025 Spruce Biosciences Inc Earnings Release
Similar to SPRB
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Spruce Biosciences share price?
As of Today at 23:25 UTC, shares in Spruce Biosciences are trading at $0.07. This share price information is delayed by 15 minutes.
How has the Spruce Biosciences share price performed this year?
Shares in Spruce Biosciences last closed at $0.07 and the price had moved by -90.04% over the past 365 days. In terms of relative price strength the Spruce Biosciences share price has underperformed the S&P500 Index by -90.77% over the past year.
What are the analyst and broker recommendations for Spruce Biosciences?
The overall consensus recommendation for Spruce Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Spruce Biosciences dividend yield?
Spruce Biosciences does not currently pay a dividend.
Does Spruce Biosciences pay a dividend?
Spruce Biosciences does not currently pay a dividend.
When does Spruce Biosciences next pay dividends?
Spruce Biosciences does not currently pay a dividend.
How do I buy Spruce Biosciences shares?
To buy shares in Spruce Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Spruce Biosciences?
As of the previous close price of $0.07, shares in Spruce Biosciences had a market capitalisation of $3.12m.
Where are Spruce Biosciences shares listed?
Here are the trading details for Spruce Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SPRB
What kind of share is Spruce Biosciences?
Based on an overall assessment of its quality, value and momentum Spruce Biosciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Spruce Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Spruce Biosciences is $1.50. That is 1931.14% above the last closing price of $0.07.
Analysts covering Spruce Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
Find out moreWhat is the trend in the Spruce Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spruce Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -86.49%.
As of the last closing price of $0.07, shares in Spruce Biosciences were trading -82.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Spruce Biosciences PE Ratio?
The Spruce Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Spruce Biosciences?
Spruce Biosciences' management team is headed by:
- Michael Grey - CHM
- Samir Gharib - PRE
- Javier Szwarcberg - CEO
- Rosh Dias - OTH
- Kirk Ways - DRC
- Tiba Aynechi - IND
- Dina Chaya - IND
- Bali Muralidhar - IND
- Niall O'donnell - IND
- Camilla Simpson - IND
- Daniel Spiegelman - IND